JPM2026会后报告

THE DEAL IS JUSTTHE BEGINNING.WE’VE GOT THEFULL STORY. #JPM2026Post JPM Summary The 44th annual J.P. Morgan Healthcare Conference (JPM) is being held in San Francisco, CAover January 12-15, 2026. Before the meeting kicks off, we have chosen a few companies towatch throughout the week to prime you for the jam-packed conference. Here we summarizethe current affairs surrounding these companies and potential discussion points to bepresented. Stay tuned for Biomedtracker’s full real-time coverage of the 2026 J.P. Morgan HealthcareConference. Our daily reports published each evening will bring you the important pipelineupdates and key takeaways from the entire day’s presentations. With our platforms helping younavigate along the way, you’ll stay informed on the latest updates in drug development and notmiss a beat from the biggest investor healthcare conference of the year. About the Author Biomedtrackeris an independent research service that offers proprietary clinical assessmentsand patient-based revenue forecasts of developmental drugs within a comprehensive andintuitive drug information database. Clients from the pharmaceutical, biotech, and investmentindustries rely on Biomedtracker for its insight on the likelihood of approval, commercialpotential, and future data and regulatory catalysts for drugs within the competitive landscapeof every important disease and indication. Over the last several years, Biomedtracker hasbecome the leader in providing objective information alongside evidencebased clinicalassessments and investment research on pipeline drugs worldwide. For more information ongetting direct access to Biomedtracker, please emailclientservices@evaluate.com. Disclaimer Copyright © 2026 Evaluate, a Norstella company. This report is published by Evaluate (thePublisher). This report contains information from reputable sources and although reasonableefforts have been made to publish accurate information, you assume sole responsibility for theselection, suitability and use of this report and acknowledge that the Publisher makes nowarranties (either express or implied) as to, nor accepts liability for, the accuracy or fitness fora particular purpose of the information or advice contained herein. The Publisher wishes tomake it clear that any views or opinions expressed in this report by individual authors orcontributors are their personal views and opinions and do not necessarily reflect the views/opinions of the Publisher. #JPM2026 Post JPM Report Table of Contents Summary ............................................................................................................. 3About the Author ................................................................................................... 3Disclaimer ............................................................................................................ 3Mega Cap.............................................................................................................. 9AbbVie................................................................................................................. 9AstraZeneca ........................................................................................................11Johnson & Johnson ...............................................................................................12Merck & Co..........................................................................................................13Novartis ..............................................................................................................14Novo Nordisk .......................................................................................................16Thermo Fisher Scientific.........................................................................................17Large Cap ............................................................................................................ 18Alcon ..................................................................................................................18Alnylam Pharmaceuticals........................................................................................19Amgen................................................................................................................20Argenx................................................................................................................21Ascendis Pharma ..................................................................................................22Bayer .................................................................................................................23BioMarin .............................................................................................................24Biogen ................................................................................................................26BridgeBio ..........................................................................................